AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts
The latest trading day saw Astrazeneca (AZN) settling at $171.61, representing a -3.85% change from its previous close.
AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail: Why You Shouldn't Panic
AstraZeneca PLC shares fell >6% after Wainua (eplontersen) failed its Phase 3 ATTR-CM trial, missing a major revenue opportunity. The stock of Ionis Pharmaceuticals, Inc., developer of eplontersen and in line for royalties on sales of eplontersen, also fell by >20%. AZN's ambitious $80bn 2030 revenue target now faces a ~$15bn gap by my calculation, but a robust late-stage pipeline and strong oncology division provide resilience.
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into a larger market.
AstraZeneca's Wainua failure hurts credibility more than valuation, Jefferies warns
The damage to AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) from Wainua's trial failure is less about the numbers than about a dent to management's credibility, according to Jefferies. The shares fell 9% and topped the FTSE 100 fallers' list, a move the broker expects to exceed the drug's actual contribution to valuation.
5 Things to Know Before the Stock Market Opens on Thursday
Stock futures are slightly higher this morning as investors monitor developments in the Middle East; PepsiCo's results narrowly beat Wall Street estimates as strength in international markets offset sluggish sales in North America; Korean memory chip maker SK Hynix is reportedly seeing heavy demand for its upcoming U.S. stock listing; AstraZeneca shares are sinking after a disappointing heart drug trial; and Levi Strauss shares are falling after the denim apparel maker issued weak guidance. Here's what you need to know today.
UK stocks decline as AstraZeneca tumbles after trial setback
The UK's FTSE 100 declined on Thursday as investors assessed renewed tensions in the Middle East, while pharmaceutical heavyweight AstraZeneca weighed heavily on the benchmark after reporting disappointing results from a late-stage clinical trial. The blue-chip FTSE 100 index fell 0.6% to 10,417.63 points by 10:45 GMT.
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
AstraZeneca shares plunge as Wainua fails late-stage heart disease trial
AstraZeneca shares slumped nearly 10% on Thursday after the drugmaker said its nerve disease treatment Wainua failed to achieve the primary objective in a late-stage clinical trial for a serious heart condition, dealing a setback to one of its most closely watched pipeline assets. The stock fell about 9.5% in London trading, making it the biggest loser on the FTSE 100 index.
AstraZeneca's £19bn blow as Wainua heart drug fails key late-stage trial
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 9.55% in early trading, wiping £19 billion from the company's valuation, after its Wainua drug failed a closely watched Phase III trial in a form of heart disease. The drop propelled the stock to the top of the FTSE 100 losers' list.
AstraZeneca stock dives 9% after heart drug trial misses target
AstraZeneca stock dives 9% after heart drug trial misses target
AstraZeneca Says Wainua Trial Failed to Meet Primary Goal
The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a placebo.
AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal
Sino Biopharmaceutical will receive $200 million upfront from AstraZeneca, and will be eligible for milestone payments.
